No material briefing disclosures were identified in the provided context for the current reporting window. The institutional ownership changes detailed below represent the primary trigger for this report, reflecting notable shifts in LLY's holder composition as of the most recent 13F filing period.
Eli Lilly's trailing twelve-month revenue stood at $72.25 billion as of 31 March 2026, representing year-over-year growth of 55.5% [SEC 10-Q - LLY - 2026-03-31]. Net income over the same period was $25.28 billion, producing a net margin of approximately 35.0% and earnings-per-share growth of 169.9% year-over-year [SEC 10-Q - LLY - 2026-03-31]. The company held $5.28 billion in cash against total debt of $43.37 billion, and the stock traded at a price-to-earnings ratio of 37.94 at the reporting date [SEC 10-Q - LLY - 2026-03-31].
Insider activity over the past 30 days recorded six transactions with a net selling direction, totalling approximately $15.75 million in net disposals [SEC Form 4 - LLY - 2026-05]. On the institutional side, Citadel reduced its position by 29% and Millennium reduced its position by 6.5%, while AQR Capital added 69% to its existing position and ARK Invest opened a new position in LLY [SEC 13F - Citadel - Q1 2026] [SEC 13F - Millennium - Q1 2026] [SEC 13F - AQR Capital - Q1 2026] [SEC 13F - ARK Invest - Q1 2026].
The broader fixed-income environment as of the report date showed the 10-year US Treasury yield at 4.57% and the 2-year yield at 4.08%, producing a normal yield curve spread of 49 basis points [FRED DGS10] [FRED DGS2]. This rate configuration represents the prevailing cost-of-capital backdrop against which LLY's debt load of $43.37 billion and its current valuation multiple are assessed by market participants.